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Abstract
Drug repurposing is the use of “old” drugs for new indications, avoiding the need for time- and 
cost-intensive toxicity studies. This approach should be particularly attractive for pediatrics, but its 
use in this population has been limited. One obstacle has been the lack of a comprehensive 
database of drugs for which there already is at least one indication in children. We describe the 
development of The Children’s Pharmacy Collaborative™, which should grow over time, serve as 
a resource for professionals and families, and stimulate drug repurposing efforts for a range of 
pediatric disorders.
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The development of new drugs is a long and expensive process [1]. Drug repurposing has 
been increasingly applied over the past decade to the use of “old” drugs with known safety 
profiles for new indications. Unlike new drug development, drug repurposing allows 
investigators to bypass or streamline toxicity studies [2], so that it appears to be a cost- and 
time-efficient strategy. This approach should be particularly attractive for pediatrics [3], 
where phase I (dose finding and toxicity) studies often are not initiated because small patient 
numbers keeps them from being economically viable [4].
Some 500 drugs have been approved by the Food and Drug Administration (FDA) for use in 
children. Thus, most medications are used off- label without having been through rigorous 
Corresponding author: Blatt, J. (jblat@med.unc.edu). 
Teaser: To address one obstacle to drug repurposing in pediatrics, we offer a comprehensive drug database which will grow over time 
and serve as a resource for professionals and families.
HHS Public Access
Author manuscript
Drug Discov Today. Author manuscript; available in PMC 2015 September 22.
Published in final edited form as:













phase I/II testing. Nonetheless, there often is a published experience of dosages and side 
effects to guide pediatric prescribers. Partial listings of such drugs are included in the Harriet 
Lane Handbook, Micromedex, Lexicomp, hospital formularies, and other commonly used 
references. Repurposing of these drugs should be acceptable to providersand patients’ 
families who may be reassured that they are “less experimental” than are most drugs in 
phase I studies. The rapidity with which the anti-hypertensive agent propranolol has become 
standard of care for treatment of infantile hemangiomas is one proof of concept [3, 5]. That 
these drugs are often less expensive should make them appealing to third-party payers.
Although many available databases include drugs which have been used in children, they do 
not include all drugs which have been used in children. Conversely, for investigators with an 
interest in pediatric disorders, most of the listings have not been used in children. Thus, 
while some compounds might potentially be of interest, they could not be repurposed 
without going through the phase I process. We offer a solution in the development of The 
Children’s Pharmacy Collaborative™, a comprehensive database of drugs for which there 
already is at least one indication for individuals under 18 years of age.
Available compound databases and repositories
Databases
The largest publicly accessible list of existing drugs is the Johns Hopkins Clinical 
Compound Library (JHCCL, www.jhccsi.org) [6]. As of 2007 the database included close to 
10,000 agents, and in turn, had been derived from drugs which had been approved by the 
FDA, drugs listed in the FDA Orange Book, the Physicians’ Desk Reference, as well as 
drugs which had entered phase II clinical trials in the United States or which had been 
approved abroad. This database listed 9,991 compounds by generic name, together with 
categories of primary indications (e.g., antiinflammatories, antineoplastics).
Repositories
Johns Hopkins and a number of other organizations have assembled repositories of drugs, a 
subset of those listed in their databases, which are publically (National Institute of 
Neurological Disorders and Stroke [NINDS], Prestwick Chemical Library, National 
Institutes of Health Chemical Genomics Center [NCGC] Pharmaceutical Collection [NPC) 
or commercially (Sigma’s Library of Pharmacologically Active Compounds [LOPAC]) 
available [7]. Several of these are limited to FDA-approved and marketed drugs. The 
National Center for Advancing Translational Sciences (NCATS) also has its Mechanism 
Interrogation PlatE (MIPE) library of oncology-focused, mechanistically annotated agents—
many of which are still investigational. Over the past 10 years, these compound collections 
have been used for preclinical screening with a view toward repurposing these old drugs.
Limitations of existing resources for pediatric drug development
Screening of these libraries against in vitro models of childhood diseases likely would 
identify active compounds. However, it also is likely that many of the “hits” would be with 
drugs which have not been used in children. Importantly, many drugs with known dosage 
and safety profiles in children may not be included in any of these databases.
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Development of the Children’s Pharmacy Collaborative™
Identification of drugs with pediatric indications
In order to identify all drugs which already have indications for patients under 18 years of 
age, we searched for each of the almost 10,000 compounds listed in the JHCCL database [6] 
online in MICROMEDEX® 2.0 (www.micromedex.com), against PubMed (using the 
generic drug name with “childhood” or “pediatrics”), and in the formulary of the Harriet 
Lane Handbook [8]. www.ClinicalTrials.gov also was searched and drugs included in our 
database which had been in phase II or III pediatric trials (i.e., for which phase I data were 
available). Although we have not yet performed a systematic review of published literature 
and abstracts, we included other agents which came to our attention and for which we 
confirmed published experience.
Information in the database
Where pediatric usage was identified, we noted whether the drug was FDA-approved for 
any indication in adults or children using www.FDA.gov and the FDA’s New Pediatric 
Labeling Information Database (http://www.accessdata.fda.gov/scripts/sda/
sdNavigation.cfm?sd=labelingdatabase), labeled and unlabeled adult and pediatric 
indications, and recommended age ranges. Drugs were listed under one of the more than 80 
categories in the JHCCL, in order to allow comparison with that database: e.g., analgesic, 
anesthetic, appetite stimulants, antacids, antibacterial/antibiotic, antiamoebic. Some drugs 
were listed as “unclassified”. These categories did not necessarily reflect what most 
clinicians would consider the primary category for which the drug is used in children. Drugs 
which did not appear in the JHCCL were assigned to one of the categories.
Data were recorded in an Excel spreadsheet which also includes columns for trade names, 
chemical names and structures [represented as Simplified Molecular-Input Line-Entry 
System (SMILES) strings], mechanism(s) of action, and one or more pharmaceutical 
companies which manufacture the drugs. The chemical structures for most of the 
compounds listed in the spreadsheet were automatically retrieved from several chemical 
databases (e.g., the National Center for Biotechnology Information, http://
www.ncbi.nlm.nih.gov/), whereas additional manual searches were conducted using in-
house and web-accessible [e.g., Chemspider (http://www.chemspider.com/) and PubChem 
(http://pubchem.ncbi.nlm.nih.gov/)] databases. All drugs, except large biologics and natural 
products presented as complex mixtures, are stored as an sdf file (see Supplementary 
Material) with initial composition and stereochemistry preserved. Chemical structures of all 
the compounds in our database are under manual verification and curation according to 
previously described guidelines (8). Many of the columns in our spreadsheet are not yet 
complete but data will be added over time. In order to allow multiple users to access the 
database, this was saved as a Google Cloud document that can be accessed by anyone but 
edited only by the authors (https://docs.google.com/spreadsheet/pub?
key=0AgsQROeRaJo8dHB2TXFBcnlMMDRjOUNhTUtpMFdTLWc&output=html). The 
database has been trademarked as “The Children’s Pharmacy Collaborative ™”.
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We identified almost 1250 drugs which had been reported series or case reports as ever 
having been used in children. 464 of these were listed in the HLH, most of which had been 
captured in MICROMEDEX® 2.0. We were able to confirm that 790 of the drugs with a 
history of pediatric usage were listed on the FDA website as having achieved FDA-labeling 
for at least one indication in adults; 456 of the drugs had any pediatric indication which was 
FDA-approved. These numbers may be overestimates, since the FDA site lists several drugs 
in duplicate or even triplicate when these have multiple brand names. In many cases, the 
FDA-approval was limited to specific age ranges (e.g., older than 10 years) despite common 
usage for a wider pediatric age range. Although these age ranges did vary for individual 
drugs depending on the indication, our database lists the youngest age for which usage is 
FDA-approved for any indication. Pediatric indications were variable, and fell into each of 
the 81 JHCCL categories. The 10 most common categories were antibiotics (n=117), which 
were listed separately from antibacterials, (n=27), antineoplastics (n=93), antihypertensives 
(n=45), antiviral (n=48), antiinflammatory drugs (n=38), anithistamines (n=34), 
anitconvulsants (n= 33), vitamins (n=27), and antipsychotics (n=24). To illustrate the 
arbitrariness of the categories, a listing of drugs which have been used in children for 
treatment of any infectious disease is given in Table 1.
Discussion
We have used a large online database of drugs as the starting point for development of a 
comparable listing which includes only drugs for which there is some experience in 
children, and which we have called The Children’s Pharmacy Collaborative™. Of the 
almost 10,000 drugs listed in the JHCCL, we confirmed that some 1250 have been used in 
individuals under the age of 18 years, the definition of a “child” commonly used by most 
pediatricians and by the FDA, and based upon the Best Pharmaceuticals for Children Act 
(BPCA) of 2002 and Pediatric Research Equity Act of 2007. While there already are a 
number of handbooks and on-line listings of drugs, our database is both more 
comprehensive (including drugs which are or have been used anywhere in the world) and 
designed specifically for pediatrics, as it includes only drugs for which there is experience in 
children. It is not meant to be a formulary with dosing or safety information, which already 
is available elsewhere. It is meant to eliminate the “background” noise of “only-used-in-
adult” drugs which which we believe clutter other drug databases. This focus should make 
the database useful to a broad audience including physicians and scientists, parents of 
children with a range of illnesses, and to pharmaceutical companies interested in drug 
repurposing for children.
Limitations to the database
There are limitations to the database. The drugs which have been used in children include 
drugs whose primary indications have been previously categorized into one of the more than 
80 categories listed by JHCCL. These categories were sometimes arbitrary in that drugs 
could have been assigned to one or another (e.g., antibacterials were separated from 
antibiotics and antiseptics; many of the immunosuppressants could have been categorized as 
antineoplastic or antiinflammatory). We have kept the same categories for ease of 
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comparison between the two databases. There is some duplication in the JHCCL (e.g., five 
insulin formulations are listed separately). We have maintained some of these in our registry 
as well, both for comparability between databases and because it seems possible that 
different formulations or chemical variants might have different activities with respect to 
new indications.
The CPC listing does not include unpublished proprietary data. Our intent is to add drugs as 
data are published or become available online. Although a number of complementary or 
alternative medicines are included in our database, this is probably not a comprehensive 
listing, as we have not yet critically examined the relevant literature.
To date, we have not listed every indication for each of the drugs in our own database. Our 
listing of indications is not meant to be complete or perfect at this time, but is simply a 
scaffold on which to build. Similarly, the FDA-approval status of drugs may change over 
time and users of the database will need to check for updated prescribing recommendations. 
Undoubtedly, there will be other criticisms of the database. We hope that ultimately the 
open access nature of the database will permit community-based improvements. The goal of 
developing a list of drugs for which there is pediatric information remains the same as for 
developing the original comprehensive database. As stated by the Johns Hopkins 
investigators, this is “to bridge the gap between lab and the clinic by finding new uses for 
existing drugs” [6].
Conclusion
“The Children’s Pharmacy Collaborative™” is the first database to focus on pediatrics, and 
confirms that drug development and labeling for children lag far behind that for adults. As 
additional new and old drugs with pediatric safety profiles are reported, these will be added 
to the database. Thus, this will grow and should be useful to a broad audience including 
physicians and scientists, parents of children with a range of illnesses, and to pharmaceutical 
companies interested in drug repurposing. A curated Wiki-website is under development, 
which we hope will allow others to participate in this process. A drug repository derived 
from the database can serve for high throughput screening and drug repurposing for a range 
of indications for which there are in vitro models such as childhood cancer, vascular 
anomalies, and chronic inflammatory disorders are only a few of these.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 1
Drugs with Pediatric Applications to Infectious Diseases













Drug Discov Today. Author manuscript; available in PMC 2015 September 22.
